Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$109.3MCash, Jun 2026
8moCash Runway (est.)
+6%Share Count, 1 Year
Follow URGN by emailGet an email when URGN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about URGN, unsubscribe in one click. Privacy
📣 What URGN Says Is Next
fourth quarter of 2026 · “UroGen’s Investigational New Drug application for UGN-501 has been accepted by the FDA, and the Company plans to initiate its Phase 1 clinical trial in NMIBC in the fourth quarter of 2026.”
Company press release, Aug 5, 2026 · SEC filing
by the end of 2026 · “The Phase 3 clinical trial evaluating UGN-104 in low-grade upper tract urothelial cancer (LG-UTUC) remains on track to complete enrollment by the end of 2026.”
Company press release, Aug 5, 2026 · SEC filing
second half of 2026 · “The Company expects to initiate a randomized controlled Phase 3 trial evaluating UGN-103 in high-risk NMIBC in the second half of 2026, and a trial evaluating UGN-103 as adjuvant therapy in newly diagnosed intermediate-risk NMIBC patients in 2027.”
Company press release, Aug 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
URGN reported $109.3M in cash and short-term investments (as of Jun 30, 2026) and used about $39.5M/quarter in operations, an estimated runway of 8.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:55 · Elevated
Cash runway 8 months +30
ATM program on file since Nov 2025 +15
Shelf registration (S-3ASR, Nov 2025) +10
Recent financing filings on SEC EDGAR:
Nov 6, 2025 · Shelf registration with ATM program, up to $75M · S-3ASR
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for URGN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.